Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar 25;7(280):280ps7.
doi: 10.1126/scitranslmed.aaa3643.

Adoptive Cellular Therapy: A Race to the Finish Line


Adoptive Cellular Therapy: A Race to the Finish Line

Carl H June et al. Sci Transl Med. .


Adoptive T cell transfer for cancer, chronic infection, and autoimmunity is an emerging field that shows promise in recent trials. Using the principles of synthetic biology, advances in cell culture and genetic engineering have made it possible to generate human T cells that display desired specificities and enhanced functionalities compared with the natural immune system. The prospects for widespread availability of engineered T cells have changed dramatically, given the recent entry of the pharmaceutical industry to this arena. Here, we discuss some of the challenges--such as regulatory, cost, and manufacturing--and opportunities, including personalized gene-modified T cells, that face the field of adoptive cellular therapy.

Similar articles

See all similar articles

Cited by 108 articles

See all "Cited by" articles

Publication types

LinkOut - more resources